Previous Close | 5.3500 |
Open | 5.2300 |
Bid | 5.0900 x 800 |
Ask | 5.1400 x 800 |
Day's Range | 4.9500 - 5.3553 |
52 Week Range | 3.6100 - 19.8000 |
Volume | |
Avg. Volume | 314,396 |
Market Cap | 14.187M |
Beta (5Y Monthly) | 1.25 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3160 |
Earnings Date | Nov 11, 2022 - Nov 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 41.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for ARTL
Recently Published Findings Support Further Development in Anxiety-Related DisordersSOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced publication of pre-clinical results indicating a novel fatty acid binding protein 5 (FABP5) inhibitor from the Company’s FABP in
CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy $21.3 Million in Cash and Investments as of June 30, 2022 15-for-1 Reverse Stock Split to be Effective August 10, 2022 SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid s
Initiates Fourth Cohort at a 650-Microgram Dose with Data Expected in Q4 2022SOLANA BEACH, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced the completion of enrollment of the first three cohorts in the Cancer Appetite Recovery Study (CAReS) and the initiation of a fourth co